Leukemic stem cell persistence in chronic myeloid leukemia patients in deep molecular response induced by tyrosine kinase inhibitors and the impact of therapy discontinuation

During the last decade, the use of tyrosine kinase inhibitor (TKI) therapy has modified the natural history of chronic myeloid leukemia (CML) allowing an increase of the overall and disease-free survival, especially in patients in whom molecular residual disease becomes undetectable. However, it has...

Descripción completa

Detalles Bibliográficos
Autores principales: Chomel, Jean Claude, Bonnet, Marie Laure, Sorel, Nathalie, Sloma, Ivan, Bennaceur-Griscelli, Annelise, Rea, Delphine, Legros, Laurence, Marfaing-Koka, Anne, Bourhis, Jean-Henri, Ame, Shanti, Guerci-Bresler, Agnès, Rousselot, Philippe, Turhan, Ali G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5085229/
https://www.ncbi.nlm.nih.gov/pubmed/27167108
http://dx.doi.org/10.18632/oncotarget.9182

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5085229/
https://www.ncbi.nlm.nih.gov/pubmed/27167108
http://dx.doi.org/10.18632/oncotarget.9182

Ejemplares similares